Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Pulse Biosciences develops nonthermal ablation devices utilizing patented Nano-pulse Stimulation (NPS) technology for medical applications in dermatology, cardiology, and soft tissue treatment. Its core product, the CellFX System, and related platforms aim to improve outcomes by precisely targeting cells while sparing surrounding tissue. The company focuses on innovative, minimally invasive therapies for conditions like benign skin lesions and atrial fibrillation, emphasizing safety, efficacy, and regulatory approval.
This description was generated via AI from an annual report. Updated about 1 year ago.